Welcome to our dedicated page for LABCORP HOLDINGS SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. executive Anita Z. Graham reported routine equity award activity. On February 11, 2026, 356 Restricted Stock Units converted into 356 shares of common stock at an exercise price of $0. To cover tax withholding, 109 shares of common stock were withheld at $289.89 per share. After these transactions, Graham directly owned 1,460 shares of common stock and 2,401 Restricted Stock Units, which continue to vest in three equal annual installments starting February 11, 2026.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported equity award activity in company stock. On February 11, 2026, he exercised 740 Restricted Stock Units, converting them into 740 shares of Common Stock at an exercise price of $0 per share.
To cover tax withholding obligations related to this vesting, 211 shares of Common Stock were withheld at a price of $289.89 per share, coded as a disposition for tax payment rather than an open-market sale. After these transactions, he directly held 31,606.9234 shares of Common Stock and 4,170 Restricted Stock Units, which vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity compensation activity involving restricted stock units and common shares. On February 11, 2026, 403 restricted stock units were converted into 403 shares of common stock, increasing her directly held common shares to 4,286. To cover tax withholding obligations, 138 common shares were withheld at a price of $289.89 per share, leaving her with 4,148 directly owned common shares. Following these transactions, she also directly holds 2,827 restricted stock units that vest in three equal annual installments beginning on February 11, 2026.
Labcorp Holdings Inc. director Paul Rothman reported acquiring shares through the vesting of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, which converted into 897 shares of Labcorp common stock at an exercise price of $0 per share.
Following this transaction, Rothman directly owned 2,571 shares of Labcorp common stock and held 773 Restricted Stock Units, which represent rights to receive the same number of common shares. The filing reflects routine equity compensation vesting rather than an open‑market purchase or sale.
Labcorp Holdings Inc. director Kathryn E. Wengel increased her direct common stock holdings through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised for 897 shares of Labcorp common stock at an exercise price of $0 per share.
After this conversion, Wengel directly owned 4,133 shares of Labcorp common stock. She also held 773 Restricted Stock Units as of that date, with each unit representing the contingent right to receive one share of Labcorp common stock upon vesting.
Labcorp Holdings Inc. director Richelle P. Parham acquired 897 shares of common stock on February 11, 2026 through the exercise and conversion of restricted stock units (RSUs) at $0 per share. This reflects equity compensation vesting rather than an open‑market purchase.
Following the transaction, Parham directly owns 3,366 shares of Labcorp common stock and holds 773 restricted stock units, each representing the contingent right to receive one share of common stock when they vest.
Labcorp Holdings Inc. director Peter M. Neupert reported the vesting and exercise of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, converting them into 897 shares of Common Stock at an exercise price of $0 per share. Following this derivative conversion, he directly owned 13,784 shares of Common Stock and 773 Restricted Stock Units, each RSU representing the right to receive one Labcorp common share.
Labcorp Holdings director Garheng Kong reported acquiring shares through the vesting and conversion of restricted stock units. On February 11, 2026, 897 Restricted Stock Units converted into 897 shares of common stock at an exercise price of $0 per share.
Each Restricted Stock Unit represents the right to receive one Labcorp common share. After this transaction, Kong directly holds 13,739 shares of common stock and 773 Restricted Stock Units, which reflects the remaining aggregate RSU balance.
Labcorp Holdings Inc. director Kirsten Marie Kliphouse reported acquiring 897 shares of common stock through the vesting and conversion of restricted stock units. The RSUs fully vested on February 11, 2026, and after the transaction she directly holds 3,160 Labcorp common shares and 773 restricted stock units.
Labcorp Holdings Inc. director Jeffrey A. Davis acquired common shares through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised/converted at $0 into 897 shares of Labcorp common stock. After this transaction, Davis directly held 5,460 common shares and 773 Restricted Stock Units.